As winter approaches and temperatures gradually drop, the risk of chronic diseases such as chronic obstructive pulmonary disease (COPD) and coronary heart disease increases. Research shows that cold weather stimulates the respiratory tract and causes vasoconstriction, significantly raising the incidence of acute exacerbations of COPD and coronary heart disease. During this high-incidence season, it is especially important to pay attention to the interaction and treatment strategies of these two common chronic diseases.
Clinically, chronic obstructive pulmonary disease (COPD) and cardiovascular diseases such as coronary heart disease often influence each other, causing or worsening conditions. Therefore, whether treating respiratory diseases like COPD or cardiovascular diseases like coronary heart disease, treatment plans must simultaneously consider both the heart and lungs. Professor Jia Zhenhua, an expert in cardiopulmonary diseases at Hebei Yiling Hospital, recipient of the State Council Special Government Allowance and a Qihuang Scholar, has applied and developed the theory of integrated heart–lung treatment based on years of clinical experience. This approach guides the treatment of complex clinical conditions such as COPD combined with coronary heart disease, effectively resolving therapeutic conflicts, improving symptoms, enhancing patients’ quality of life, and achieving favourable outcomes.
Lung and Heart Diseases: COPD Can Trigger or Worsen Coronary Heart Disease
Respiratory diseases can cause airflow limitation, which not only impairs normal respiratory function but also, over the long term, can induce or exacerbate cardiovascular diseases such as coronary heart disease. Taking COPD as an example, this chronic respiratory disease is characterised by partially irreversible airflow limitation. This means that airway hyperresponsiveness causes bronchospasm and other symptoms leading to breathing difficulties; even after the spasm resolves, normal ventilation is not fully restored, and airflow limitation persists, manifesting as shortness of breath, wheezing, and chest tightness. Due to prolonged airflow limitation, COPD patients often experience hypoxia, resulting in insufficient oxygen supply to the myocardium and increased cardiac workload, thereby triggering or worsening coronary heart disease. Related studies indicate a close correlation between airflow limitation and coronary heart disease, with an increased risk of coronary heart disease among COPD patients.
Heart Disease and Lung Disease: Coronary Heart Disease Can Increase the Risk of COPD
Not only can COPD trigger or worsen coronary heart disease, but patients with coronary heart disease also have an increased risk of developing respiratory diseases such as COPD. Cardiovascular disease is the leading cause of death among COPD patients and significantly increases their hospitalisation rates and long-term mortality. Professor Jia Zhenhua notes that whether it is COPD or coronary heart disease, patient prognosis is affected by comorbidities; when these two chronic diseases coexist, prognosis worsens, making treatment more challenging. Among coronary heart disease patients, those with concurrent COPD have a higher risk of myocardial infarction and increased mortality. Research shows that patients with ST-segment elevation myocardial infarction combined with COPD have significantly higher rates of rehospitalisation due to recurrent myocardial infarction, coronary artery revascularisation, heart failure, severe bleeding, and an increased risk of death.
Heart and Lung Comorbidity: Therapeutic “Conflicts” Make Treatment Difficult
In clinical treatment, if a patient has both heart and lung diseases—for example, COPD combined with coronary heart disease—it is necessary to effectively improve and relieve symptoms caused by airflow limitation and lung function impairment, while also improving myocardial blood supply. However, in practice, most Western medicines currently used to treat COPD can significantly alleviate clinical symptoms but cannot reverse the progressive decline in lung function. More challenging is that the therapeutic benefits of related drugs for patients with both COPD and coronary heart disease are contradictory. For example, β-blockers are a cornerstone treatment for coronary heart disease but are relatively contraindicated in COPD; β-agonists are important in treating COPD but carry risks of increased tachycardia, heart failure, and cardiovascular death, creating a therapeutic dilemma.
Integrated Heart–Lung Treatment: Symptom Improvement through Traditional Chinese Medicine
To address this treatment challenge, Professor Jia Zhenhua and his research team, based on traditional medical theory and summarising years of clinical experience, have developed and applied the integrated heart–lung treatment theory. This guides the treatment of COPD combined with coronary heart disease and has achieved favourable results in improving symptoms and enhancing quality of life.
Traditional Chinese Medicine has long established the preliminary concept of the “heart (lung)–blood–vessels” circulatory system, discussing the close connection between the heart and lungs. Physiologically, the heart and lungs coordinate with each other; pathologically, disease in either organ affects the other. Heart blood stasis impairs the lung qi’s respiratory function; lung qi deficiency adversely affects heart blood circulation. Building on this, Academician Wu Yiling proposed the new concept of “heart–lung correlation” and “integrated heart–lung treatment.” Professor Jia Zhenhua and his team have conducted in-depth clinical exploration and application, using methods to tonify the ancestral qi and defensive qi, regulate the interaction of nutritive and defensive qi, dispel phlegm, blood stasis, and toxic pathogens, achieving integrated heart–lung treatment combined with conventional Western medicine for COPD complicated by coronary heart disease.
Under the guidance of the “integrated heart–lung treatment” concept, Hebei Yiling Hospital has led clinical research on COPD combined with coronary heart disease. The study results show that traditional Chinese medicine integrated heart–lung treatment combined with conventional Western medicine for stable COPD with stable coronary heart disease achieves better efficacy compared to Western medicine alone. This is reflected in significant symptom improvement, enhanced exercise capacity and quality of life, and a reduction in some adverse effects associated with certain Western medicines.




